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Abstract: Fundamental physical properties, such as the intrinsic recoil of the lung, are 
governed by the extracellular matrix. The prototypical roles of the matrix proteins, collagen and 
elastin, in pulmonary ﬁ  brosis and emphysema have long been recognized, and much research 
effort has been devoted to understanding mechanisms of extracellular matrix synthesis and 
turnover in the lung. Yet, despite extensive knowledge of the biochemical properties of col-
lagen and elastin, none of the present clinical strategies for treating COPD directly target the 
extracellular matrix. From a matrix perspective, therapeutic interventions that limit elastic ﬁ  ber 
destruction and/or restore function to damaged alveolar units merit particular consideration 
as clinical strategies for treating the emphysema component of COPD. Effective treatment 
of the bronchiolar component of COPD requires a better understanding of the relationship 
between airway ﬁ  brosis and airﬂ  ow obstruction. Translating basic knowledge of extracellular 
matrix biology into the clinical venue will be essential in the development of new approaches 
to COPD treatment.
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Introduction
The extracellular matrix is assembled into distinct three dimensional structures that 
play a key role in determining the physical and mechanical properties of an organ. 
In the lung, extracellular matrix organization is highly specialized to facilitate 
gas exchange. Lung extracellular matrix is partitioned into cartilage, provisional 
matrix, basement membrane, and interstitium. A brief discussion of the compart-
mentalization of lung extracellular matrix is found in the ﬁ  rst part of this review. 
The extracellular matrix is composed of discrete gene products with speciﬁ  c func-
tions. The basic biology of collagens and elastic ﬁ  bers, matrix components that 
are fundamental to lung structure and function, is summarized in the next section. 
The review concludes with a description of COPD pathology that is associated with 
the extracellular matrix and a perspective on therapeutic strategies for COPD based 
on matrix-related pathology.
Extracellular matrix compartments in the lung
Cartilage
The walls of the trachea and large bronchi are lined by cartilage. Collagen ﬁ  bers located 
in the outer layers of cartilage oppose tensile forces and proteoglycans in the central 
zone resist compression forces on the airways so that the changes in intrathoracic pres-
sure that occur during breathing do not effect airway collapse (Roberts et al 1998).
Provisional matrix
Provisional matrices are assembled during development or wound repair and are 
degraded when normal tissue architecture is achieved. The most common provisional 
matrix components are ﬁ  bronectin and ﬁ  brin. Thrombospondin, tenascin, and SPARC 
may also form provisional matrix in the lung.International Journal of COPD 2008:3(1) 114
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Basement membranes
Basement membranes are found wherever parenchymal 
cells juxtapose connective tissue (Figure 1). Basement 
membranes provide physical support for an organ and also 
regulate macromolecular diffusion. In the lung, the type 
I alveolar epithelial and capillary endothelial basement 
membranes are fused thus providing a minimal barrier 
for gas diffusion. At the biochemical level, speciﬁ  c base-
ment membrane components can modulate cell phenotype 
through direct interactions with cell surface receptors. 
Integrins are the best characterized cell surface recep-
tors for matrix proteins and mediate both mechanical and 
chemical signals which activate a variety of intracellular 
signaling pathways to affect cell proliferation, survival, 
and differentiation (for review see Hynes 2002; Danen and 
Sonnenberg 2003; Hynes 2004). Airway branching and 
alveolar epithelial cell localization are inﬂ  uenced by the 
interactions of basement membrane components such as 
type IV collagen, laminin, ﬁ  bronectin, and proteoglycans 
with cell surface receptors.
The pulmonary interstitium
The pulmonary interstitium is located between the airspace 
epithelium and pleural mesothelium. Fibers of the matrix 
proteins, collagen and elastin, are the major components of 
the pulmonary interstitium. The primary function of these 
ﬁ  bers is to form a mechanical scaffold that maintains struc-
tural integrity during ventilation (Figure 2). It has long been 
recognized that devastating pathology can result from disrup-
tion of pulmonary interstitial matrix homeostasis. Increased 
extracellular matrix synthesis and deposition, particularly 
of types I and III collagen, epitomizes pulmonary ﬁ  brosis. 
In ﬁ  brotic lungs, gas exchange is adversely affected by the 
obliteration of capillary beds and decreased regional compli-
ance caused by the thickening of the pulmonary interstitium. 
Conversely, extracellular matrix degradation is a character-
istic of pulmonary emphysema (Mandl et al 1977; Barnes 
2004). In this disease, ventilation is negatively affected by 
the decreased intrinsic recoil of the lung that results from 
proteolytic destruction of elastic ﬁ  bers (Christie 1934; Stead 
et al 1952; Mead et al 1955; Cherniack 1956).
Figure 1 Basement membrane organization. Epithelial cells are linked to connective tissue via a network of matrix proteins. Laminin 5 connects integrins on the basal surface 
of epithelial cells to the type IV collagen network in the lamina densa of the basement membrane. Anchoring ﬁ  brils composed of type VII and type XV collagen link the base-
ment membrane to the interstitial matrix where type I collagen, type III collagen and elastic ﬁ  bers are found. Integrins located on the ﬁ  broblast cell surface interact with many 
matrix proteins including type I collagen. Copyright © 2003, 2007. Modiﬁ  ed with permission from Dunsmore SE, Chambers RC, Laurent GJ. 2003. Matrix Proteins. Figure 2.1.2. 
In: Respiratory Medicine, 3rd ed. London. Saunders, p. 83; Dunsmore SE, Laurent GJ. 2007. Lung Connective Tissue. Figure 40.1. In: Chronic Obstructive Pulmonary Disease: 
A Practical Guide to Management, 1st ed. Oxford. Wiley-Blackwell, p. 467.
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Structural components 
of the pulmonary interstitium
Collagens
In simple terms, collagens may be thought of as the ‘struts’ 
of the lung; rod-like structures that limit lung deformation. 
The rod-like structures are composed of different types of 
collagen chains all of which contain a characteristic repeating 
sequence of three amino acids (Gly-x-y). Gly-x-y sequences 
associate to form triple helices, and by deﬁ  nition, all colla-
gens contain at least one triple helical region (van der Rest 
and Garrone 1991). Collagen function is dependent on the 
formation of supramolecular structures from speciﬁ  c collagen 
polypeptide chains (Figure 3).
Fibrillar collagens (types I, II, III, V, and XI) are the 
most abundant proteins in the lung constituting approxi-
mately 15% to 20% of the dry weight of the tissue (Pierce 
and Hocott 1960). The primary function of ﬁ  brillar col-
lagens is to provide tensile strength to all distensible 
components of the lung. Types I and III collagen perform 
this function in the alveolar interstitium, pulmonary blood 
vessels, visceral pleura, and connective tissue sheaths that 
surround the tracheobronchial tree. Types II and XI col-
lagen are responsible for the tensile strength of bronchial 
and tracheal cartilage. Type IV collagen, the predominant 
component of basement membranes, is the most abundant 
nonﬁ  brillar collagen in the lung. The amino and carboxy 
terminal regions of the type IV collagen molecule laterally 
associate to form open-network structures that confer tensile 
strength to the blood-gas barrier and prevent stress failure 
of the pulmonary capillaries under normal conditions (West 
and Mathieu-Cosello 1999).
Elastic ﬁ  bers
Simplistically, elastic fibers are the springs that snap 
the lung back to resting volume following inﬂ  ation. The 
primary component of elastic ﬁ  bers (Kielty et al 2002), 
elastin (Mithieux and Weiss 2005), is composed mainly of 
hydrophobic amino acids (44%), glycine (33%), and proline 
(10%–13%). Two pentapeptides Val-Pro-Gly-Val-Gly and 
Pro-Gly-Val-Gly-Val repeat frequently in the molecule and 
are thought to form large spiral regions which contribute to 
the unique distensibility of the protein (Li and Daggett 2002). 
In the lung, elastic ﬁ  bers are predominately found in the 
parenchyma where together with collagen ﬁ  brils, an integral 
ﬁ  ber network which comprises the architectural skeleton of 
the lung is formed. Supramolecular assembly of elastic ﬁ  bers 
in the lung is distinct. In the walls of the pulmonary artery and 
arterioles, elastic ﬁ  bers are organized into concentric sheets 
or lamellae. Elastic ﬁ  bers encircle respiratory bronchioles 
and alveolar ducts in a helical fashion and appear as a ﬁ  ne 
mesh in alveolar walls.
Figure 2 Pulmonary interstitium. At the gas exchange interface alveolar capillaries and alveolar type I epithelial cells share a basement membrane. In other portions of the 
alveolar wall, collagen ﬁ  brils and elastic ﬁ  bers are the major components of the pulmonary interstitium which also contains ﬁ  broblasts and proteoglycans. Copyright © 2003, 
2007. Modiﬁ  ed with permission from Dunsmore SE, Chambers RC, Laurent GJ. 2003. Matrix Proteins. Figure 2.1.1. In: Respiratory Medicine, 3rd ed. London. Saunders, 
p. 83; Dunsmore SE, Laurent GJ. 2007. Lung Connective Tissue. Figure 40.2. In: Chronic Obstructive Pulmonary Disease: A Practical Guide to Management, 1st ed. Oxford. 
Wiley-Blackwell, p. 468.
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Figure 3 Collagen supramolecular structures. Copyright © 2005. Modiﬁ  ed with permission from Dunsmore SE. 2005. Extracellular Matrix: Collagens. Figure 2 In: Encyclopedia 
of Respiratory Medicine, 1st ed. London. Academic Press, p. 173; Dunsmore SE, Laurent GJ. 2007. Lung Connective Tissue. Figure 40.3. In: Chronic Obstructive Pulmonary 
Disease: A Practical Guide to Management, 1st ed. Oxford. Wiley-Blackwell, p. 470.International Journal of COPD 2008:3(1) 117
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When appropriately assembled, elastic ﬁ  bers will last 
for the entire life span of an organism (Shapiro et al 1991). 
Enzymatic cross-linking of tropelastin lysine residues 
(Bedell-Hogan et al 1993; Thomassin et al 2005) and a 
transglutaminase cross-link between tropoelastin and ﬁ  bril-
lin-1 (Rock et al 2004) are required for elastic ﬁ  ber assembly 
(Figure 4). Other molecules such as ﬁ  bulins (Nakamura et al 
2002; Yanagisawa et al 2002; McLaughlin et al 2006) play 
important roles in tethering elastic ﬁ  bers to cells during 
the assembly process. Elastic ﬁ  bers cannot be repaired or 
replaced, thus irreversible pathology will result from elastin 
degradation. Recent evidence suggests that defects in elastic 
ﬁ  ber assembly may enhance susceptibility to proteolysis 
(Kelleher et al 2005).
Matrix-related pathology of COPD
Although the etiology of COPD can often be ascribed to 
a single factor (α1antitrypsin deficiency or exposure to 
cigarette smoke), the extracellular matrix-related pathol-
ogy observed in COPD patients is rarely uniform. Airway 
ﬁ  brosis and emphysema are the most obvious pathological 
changes and are described in further detail below. Cartilage 
degeneration may accompany airway fibrosis in COPD 
patients (Haraguchi et al 1999). Marked changes in the airway 
(Cosio et al 1980; Jeffery 2001) and alveolar epithelium 
(Otto-Verberne et al 1991) occur in COPD implying coexist-
ing basement membrane aberrations. The compartmentaliza-
tion and complexity of the lung extracellular matrix and the 
nonuniform nature of its response to the intrinsic and extrinsic 
factors associated with COPD should be taken into account 
when designing therapeutic strategies for COPD treatment.
Airway ﬁ  brosis
Deposition of collagenous and noncollagenous matrix pro-
teins in the airways is part of a larger remodeling process 
which also includes changes in airway smooth muscle and 
mucous glands. Historically, the ratio of mucous gland size 
to bronchial wall thickness (Reid 1960) was used to patho-
logically diagnose chronic bronchitis in the central airways 
(4 mm in diameter). Thickening of the bronchial walls 
due to TGF-β mediated collagen deposition is evident in the 
central airways of patients with chronic bronchitis (Vignola 
et al 1997), but the symptoms of chronic bronchitis do not 
appear to be predictive of the rapid decline in forced expira-
tory volume that occurs in COPD (Peto et al 1983; Vestbo 
and Lange 2002).
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Figure 4 Elastic ﬁ  ber assembly. Fiber assembly begins on the surface of elastogenic cells where interactions with integrins are important for microassembly of tropoelastin and 
ﬁ  brillin. The enzymes, lysyl oxidase (LOX) and lysyl oxidase-like 1 (LOXL) begin to catalyze the oxidative deamination of lysine and hydrolysine residues on the tropoelastin 
globules ( ) that accumulate on the cell surface and continue the cross-linking process as the globules assemble on the microﬁ  brillar scaffold ( ) in the extracellular space.International Journal of COPD 2008:3(1) 118
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Airway obstruction in the smaller conducting airways 
(2 mm in diameter) does correlate with the overall sever-
ity of COPD (Hogg et al 2004). In severe disease (GOLD 
stage 3 and GOLD stage 4), thickness of all components of 
the small airway wall (epithelium, lamina propria, smooth 
muscle, adventitia) is increased (Hogg et al 2004). Fibrosis 
in the small airways is not well characterized. It is assumed 
that persistent inﬂ  ammation in the small airways initiates a 
process of epithelial injury and repair and that ﬁ  brosis results 
from the subepithelial deposition of ﬁ  bronectin and tenascin 
and the adventitial accumulation of collagen types I and III. 
Some modeling studies suggest that extracellular matrix 
deposition in the airways may be a teleological response to 
prevent airway collapse (Pare 1997). In COPD, however, the 
increased thickness of the walls of the small airways appears 
to directly lead to pathological narrowing of the airway lumen 
(Bosken et al 1990).
Emphysema
Emphysema is typically classiﬁ  ed as either panacinar or cen-
trilobular. Panacinar emphysema predominates in the lower 
lung zones and results from α1-antitrypsin deﬁ  ciency. Uni-
form destruction of the alveolar walls and permanent enlarge-
ment of the alveoli are observed. As the disease progresses, 
all respiratory airspaces distal to a terminal bronchiole are 
affected. Centrilobular emphysema predominates in the upper 
lung zones and begins with inﬂ  ammation in the terminal and 
respiratory bronchioles with subsequent enlargement of the 
alveoli and more distal respiratory airspaces. Centrilobular 
emphysema is a consequence of prolonged exposure to 
cigarette smoke.
Therapeutic strategies for COPD
Current COPD treatment regimens are designed to slow 
progression of the disease. Therapies may be behavioral 
(smoking cessation), pharmacological (bronchodilators, 
corticosteroids), replacement (α1-antitrypsin augmentation), 
or supportive (oxygen supplementation, pulmonary rehabili-
tation, nutritional support). In severe COPD cases, surgical 
intervention (lung volume reduction, transplant) may be an 
option. From a matrix perspective, therapeutic strategies 
that limit elastic ﬁ  ber destruction and/or restore function to 
damaged alveolar units will most likely improve the clinical 
outcome of COPD. It is unclear if speciﬁ  c treatments for 
airway ﬁ  brosis, which remain to be developed, will prove to 
be beneﬁ  cial in the COPD patient. Perspectives on protease 
inhibition, ﬁ  brosis reversal and alveolar regeneration in the 
context of COPD treatment ensue.
Protease inhibition
Ever since the discovery of the association of α1-antitrypsin 
deﬁ  ciency with emphysematous lung disease (Laurell and 
Ericksson 1963; Ericksson 1964), much effort has been 
focused on the design of neutrophil elastase inhibitors for 
COPD treatment. Indeed, the elastase-antielastase hypothesis 
has dominated the ﬁ  eld of COPD research for the past 40 
years. Many compounds designed to inhibit neutrophil elas-
tase have been tested in animal models and in clinical trials 
(Ohbayashi 2002), but α1-antitrypsin remains the only neutro-
phil elastase inhibitor used in the routine clinical treatment of 
COPD. The design of therapeutic strategies based on antipro-
teases is complicated by the broad spectrum of extracellular 
and intracellular proteases, many with elastolytic capacity, 
that are present in the COPD patient (Shapiro 2001). Data 
from animal models (Hautamaki et al 1997; Zheng et al 2000) 
indicate that proteases other than neutrophil elastase may be 
important in elastic ﬁ  ber destruction and COPD pathogenesis. 
Though it appears that the protease-antiprotease hypothesis 
may be more extensive than originally envisioned, effec-
tive inhibition of elastolytic proteases will continue to be 
an attractive strategy for attenuating COPD progression. 
Inhibition of nonelastolytic proteases may also be an effec-
tive strategy for limiting structural damage to the epithelium 
and basement membrane.
Fibrosis reversal
Since bronchodilators do appear to alleviate some COPD 
symptoms (Weder and Donohue 2005), discussion of whether 
treatments that reverse airway ﬁ  brosis will be a stable and 
long-term means of preventing airﬂ  ow obstruction may be 
warranted. Bronchial wall thickness and core-rind heteroge-
neity are the most predictive features of declining pulmonary 
function in COPD (Aziz et al 2005), but it is not known if 
modulation of bronchial wall thickness will correlate with 
improved pulmonary function in COPD. Data from computed 
tomography analyses may be used to develop prognostic 
algorithms for how changing bronchial wall thickness in an 
emphysematous lung affects pulmonary function. Animal 
models in which airway ﬁ  brosis can be uncoupled from 
emphysema in the presence and absence of inﬂ  ammation are 
technically feasible and will be available for in vivo proof of 
concept testing of candidate molecules with ﬁ  brosis-reversing 
properties. Antiﬁ  brotic actions of potential therapeutics are 
likely to be cell type-speciﬁ  c, and potential antiﬁ  brotic agents 
as well as anti-inﬂ  ammatory compounds already in clinical 
use should be tested in in vitro models in which the matrix-
producing capacity of the structural cells of the airway wall International Journal of COPD 2008:3(1) 119
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can be assessed. Recent evidence suggests that therapies that 
are equivalent in reducing inﬂ  ammation may have dissimilar 
effects on ﬁ  brosis (Burgess et al 2006).
Several pharmacologics designed to inhibit or prevent 
ﬁ  brosis in the lung are in various stages of clinical devel-
opment (Table 1). Most of these compounds have been 
designed to block the effects of cytokines on ﬁ  broblasts so 
that ﬁ  broblast proliferation and excess matrix production can 
be inhibited. Clinical trials testing the anti-ﬁ  brotic efﬁ  cacy 
of drugs originally developed to treat other indications have 
also been conducted (Table 2). At the present time, however, 
the optimal pharmacotherapy for ﬁ  brosis reversal in any lung 
disease remains elusive.
Airway ﬁ  brosis in COPD is preceded by chronic bronchial 
inﬂ  ammation. Thus, anti-inﬂ  ammatory treatment if admin-
istered at the appropriate disease stage could potentially 
prevent the development of pathologic airway ﬁ  brosis in the 
COPD patient. Furthermore, many current anti-inﬂ  ammatory 
therapies may have direct effects on the production of matrix 
proteins. For instance, glucocorticoids can inhibit the syn-
thesis of collagen (Bavetta et al 1962; Shull and Cutroneo 
1983; Oikarinen et al 1988). Phosphodiesterase 4 inhibitors 
block TGF-β induced collagen production in airway smooth 
muscle cells (Burgess et al 2006). Animal model data suggest 
that corticosteroids (McMillan et al 2005; Cho et al 2005; 
Miller et al 2006) and antileukotrienes (Henderson et al 
2006) may be effective at reversing airway ﬁ  brosis. Effects of 
anti-inﬂ  ammatory therapeutics on airway ﬁ  brosis merit con-
sideration as strategies for application of pharmacotherapy 
to COPD become more speciﬁ  cally adapted to disease stage 
and genetic background.
Alveolar regeneration
To completely restore normal lung function to the COPD 
patient, repair and regeneration of damaged alveolar units 
is necessary. Clinical implementation of regenerative medi-
cine remains a revolutionary and futuristic goal, but data 
from animal studies is providing evidence of some critical 
components of this process. The complexity of alveolar 
development is illustrated by the reports of defective alveo-
genesis in at least 11 distinct ‘knock-out’ mice (Mahadeva 
and Shapiro 2002; Banerjee et al 2004; Chiang et al 2005; 
Mandeville et al 2006). Alveolar enlargement in mice 
deﬁ  cient in surfactant protein D (Wert et al 2000), TIMP-3 
(Leco et al 2001), or the β6 integrin subunit (Morris et al 
2003) underscores the importance of these molecules in regu-
lating alveolar homeostasis. Models in which emphysema is 
induced by apoptosis of alveolar endothelial (Kasahara 2000) 
or epithelial cells (Aoshiba et al 2003) highlight the role of 
parenchymal cell turnover in the maintenance of alveolar 
structure. Perhaps the most promising ﬁ  nding from animal 
studies is that in elastase-damaged lungs, alveolar function 
and architecture can be restored by retinoic acid treatment 
(Massaro and Massaro 1997). Translation of these ﬁ  ndings in 
animal studies to clinical practice represents one of the most 
promising and challenging areas of COPD research.
In COPD, the capacity of the type II pneumocyte to 
proliferate and to restore the alveolar epithelium may be 
exhausted. Thus, alveolar regeneration might depend on the 
repopulation of damaged areas of the lung by stem cells. 
Recent progress indicates that “ethically acceptable” sources 
of human embryonic stem cells may be available for clinical 
use (Klimanskaya et al 2006). Understanding the pathways 
by which embryonic stem cells can be induced to differenti-
ate into type II pneumocytes (Ali et al 2002), however, may 
provide sufﬁ  cient information to develop either a pharma-
cological or biological means of stimulating proliferation of 
epithelial cells in emphysematous lungs.
Hematopoietic stem cells can also serve as progenitors 
for the alveolar epithelium (Krause et al 2001; Kotton et al 
2001). Human pulmonary chimerism is observed following 
bone marrow transplant (Suratt et al 2003; Mattsson et al 
2004; Albera et al 2005) and appears to be increased in the 
setting of chronic injury (Kleeberger et al 2003). Although 
it is likely that proliferation of type II pneumocytes is the 
predominant mechanism by which alveolar repair occurs 
(Zander et al 2005), hematopoietic stem cell engraftment 
may be particularly important for repair of areas of the lung 
in which emphysema has begun to develop. Clinical proto-
cols for mobilizing hematopoietic stem cells are available 
should the engraftment of bone marrow-derived cells in the 
emphysematous lung prove beneﬁ  cial.
Table 1 Compounds in clinical development for treatment of ﬁ  brotic lung disease
Compound Proposed  mechanism  Status
BIBF 1120  Inhibits VEGF, PDGF and FGF receptors  Phase II clinical trial (NCT00514683)
FG 3019  CTGF neutralizing antibody  Phase I clinical trial (NCT00074698)
GC1008 TGF-β neutralizing antibody  Phase I clinical trial (NCT00125385)
Pirfenidone  Inhibits collagen synthesis and ﬁ  broblast proliferation  Phase III clinical trials (NCT00287716, NCT00287729)International Journal of COPD 2008:3(1) 120
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Conclusions
Matrix-related pathology underlies many COPD symptoms. 
Treatments that restore lung function in COPD are needed. 
Knowledge of extracellular matrix biology can provide a basis 
for the development of new approaches to COPD treatment.
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